5Pallardy M.Induclion of apoptosis in lymphocytes by glucocorticoids:between physiology and pharmacology[J].C R Seances Soc Biol Fil, 1998; 192:1051 - 1063.
7Sonia L,Planey.Glucocorticoid-lnduced Apoptosis in Lymphocytes[J]. Biochemical and Biophysical Research Communications,2000;279(2):307-312.
8Zhang Z,Jones S,Hagod JS,et al.STAT3 acts as a coactivator of glucocorticoid receptor singaling[J].J Biol Chem, 1997;272:30607-30610.
9Auphan N,Didonata JA,Rosette C,et al.Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis[J]. Science, 1995;270:286-290.
10Almawi WY, Beyhum HN,Rahme AA,et al.Regulation of cytokine and cytokine receptor expression by gtucocorticoids[J].J Leukoc Biol, 1996;60:563-572.
1Kisiel B, Bednarczuk T, Kostrzcwa G, et al.Polymorphism of the ocstrogen receptor beta gene (ESR2) is associated with susceptibility to Graves' disease[J]. Clin Endocrinol (Oxf),2008; 68(3):429 -434.
2Jazdzewski K, Bednarczuk T, Stepnowska M,et al.beta-2-adrenergic receptor gene polymorphism confers susceptibility to Graves disease[J]. Int J Mot Med, 2007;19(1):181 - 186.
3Rivkees SA.Pediatric Graves' disease: controversies in management[J]. Horm Res Paediatx, 2010;74(5):305 - 311.
4Mudrikova T, Jureova V, Tokareikovfi A,et al.Effeet of bisoprolol on heart rate variability in patients with hyperthyroidism[J]. Vnitr Lek, 2000; 46(2):87- 91.
5Stan MN, Bahn RS.Risk factors for development or deterioration of Graves' ophthalmopathy[J]. Thyroid, 2010;20(7):777- 783.
6Liu CJ5Dong YY,Wang YW,et al.Efficiency analysis of using tailored individualdoses of radioiodine and fine tuning using a low-dose antithyroid drug in thetreatment of Graves ’ disease[J].Nucl Med Commun,2011;32(3):227-232.
7Jukic T,Stanicic J,Petrie V,et al.Radioiodine versus surgery in the treatment of Graves’ hypei1hyroidism[J].Lijec Vjesn,2010;132(11-12):355-360.
